Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2014 / Article
Special Issue

Oxidants and Antioxidants in Metabolic Syndrome and Cancer

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 823071 | https://doi.org/10.1155/2014/823071

Wenjing Li, Xiaoyan Yang, Shasha Xing, Fang Bian, Wanjing Yao, Xiangli Bai, Tao Zheng, Guangjie Wu, Si Jin, "Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall", Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 823071, 11 pages, 2014. https://doi.org/10.1155/2014/823071

Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall

Academic Editor: Shiwei Deng
Received13 Feb 2014
Revised17 Mar 2014
Accepted21 Mar 2014
Published10 Apr 2014


Oxidized low density of lipoprotein (oxLDL) is the major lipid found in atherosclerotic lesion and elevated plasma oxLDL is recognized to be a risk factor of atherosclerosis. Whether plasma oxLDL could be transported across endothelial cells and initiate atherosclerotic changes remains unknown. In an established in vitro cellular transcytosis model, the present study found that oxLDL could traffic across vascular endothelial cells and further that the regulation of endogenous ceramide production by ceramide metabolizing enzyme inhibitors significantly altered the transcytosis of oxLDL across endothelial cells. It was found that acid sphingomyelinase inhibitor, desipramine (DES), and de novo ceramide synthesis inhibitor, myriocin (MYR), both decreasing the endogenous ceramide production, significantly inhibited the transcytosis of oxLDL. Ceramidase inhibitor, N-oleoylethanolamine (NOE), and sphingomyelin synthase inhibitor, O-Tricyclo[,6]dec-9-yl dithiocarbonate potassium salt (D609), both increasing the endogenous ceramide production, significantly upregulated the transcytosis of oxLDL. In vivo, injection of fluorescence labeled oxLDL into mice body also predisposed to the subendothelial retention of these oxidized lipids. The observations provided in the present study demonstrate that endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes the initiating step of atherosclerosis—the subendothelial retention of lipids in vascular wall.

1. Introduction

Atherosclerosis (AS) is the pathological basis of cerebro- and cardiovascular diseases, which are the leading causes of death in the elderly people [1]. The pathogenesis of AS is far from fully understood. In recent years, more and more evidences show that the initiating step of AS is likely to be the subendothelial retention of lipoprotein in intima, so called “response to retention” hypothesis [25], which highlights the role of accumulation of apoB-containing lipoproteins (mainly low density lipoprotein, LDL) in the subendothelial space, as well as extracellular matrix adhesion molecules, and so forth in the pathogenesis of AS.

To be deposited in the vascular intima, lipoproteins must pass through the barrier provided by vascular endothelium. The gap between the vascular endothelial cells is known to be about 3–6 nm in diameter, only allowing water, inorganic salts, and a handful of small proteins to pass through. Such macromolecule molecules as LDL in a diameter of about 20–30 nm are not generally able to pass through the endothelial barrier [68].

Recent studies have found LDL traffic across endothelial barrier mainly through transcytosis [9], which refers to a process of protein-rich particles passing through polar cells (such as endothelial cells, epithelial cells, etc.) by receptor or nonreceptor mediated mechanisms. LDL can be endocytosed by vascular endothelial cells in the lumen side and then exocytosed to the basolateral side [9]. A large number of studies have documented that the major LDL accumulated in AS plaques is in the oxidative modified form, namely, oxidized low density lipoprotein, oxLDL. Currently, oxLDL is recognized as the major causative factor of AS [10, 11]. Plasma oxLDL levels were significantly increased in AS patients and have been considered as indicators of the early screening and diagnosis of coronary heart disease [12, 13]. Whether plasma oxLDL can pass through endothelial cells by transcytosis and further stick to intima to initiate the incidence of AS remains unknown.

In recent years, the role of lipid rafts (LRs) in the transmembrane transport of macromolecules has attracted much more attention [1417]. Lipid rafts are membrane domains rich in sphingolipids and cholesterol [18, 19]. Endothelial caveolae used for LDL transcytosis is a specialized membrane raft domain [15]. Membrane fusion between vesicle membranes and sarcoplasmic membranes due to the formation of macromolecular complexes, such as t-SNARE and v-SNARE, is also dependent on the platform formed by fusion of membrane rafts [9]. Ceramide, the backbone of sphingolipids, is thought to participate in the development of atherosclerosis [20, 21]. Ceramide can be generated from sphingomyelin through activation of sphingomyelinase (SMases) or from the de novo pathway. Also, ceramide can be synthesized to sphingomyelin through activation of sphingomyelin synthase (SMS) or degraded into sphingosine by ceramidase, respectively. Inhibitors involved in ceramide metabolism commonly including acid sphingomyelinase (ASM) inhibitor, desipramine [2224], de novo ceramide synthesis inhibitor, myriocin [25], ceramidase inhibitor (NOE) [26, 27], and sphingomyelin synthase inhibitor (D609) [28, 29].

Upon the stimulation of endogenous and exogenous factors, the sphingolipid (sphingomyelin) in endothelial cell membrane rafts undergoes hydrolysis by acid sphingomyelinase, releasing the hydrophilic phosphocholine group and generating hydrophobic product, ceramide [15]. The existence of intermolecular hydrogen bonds provides strong driving force for ceramide to fuse simultaneously. Through the integration of ceramide, many small membrane rafts can cluster together into larger microdomains, which provide signaling platforms for the interaction of transmembrane signal transduction [3032]. Recent studies have also found that the ceramide produced by membrane rafts plays key roles in pathogen invasion into host cells, such as Pseudomonas aeruginosa [3335]. In addition, ceramide can trigger and promote the exocytosis of Weibel-Palade bodies in endothelial cells [23].

Given the multiple origins of cellular ceramide, the current study aims to determine the roles of ceramide from different origins in mediating the transcytosis of oxLDL across the vascular endothelial cells and how these transcytosed oxLDL particles further promote AS changes in vascular walls.

2. Methods

2.1. Isolation and Culture of Human Umbilical Vein Endothelial Cells (HUVECs)

The collection of human umbilical cords was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China), and conducted in accordance with the Declaration of Helsinki (2008). Primary HUVECs isolated from 0.01% EDTA-0.25% trypsin digested newborn umbilical cord were cultured in ECM (ScienCell) supplemented with 5% fetal bovine serum (FBS), 100 U/mL penicillin, 100 U/mL streptomycin, and 30 μg/mL endothelial cell growth supplement (ECGS) at 37°C under 5% CO2 in a humidified atmosphere. For subculture, cells were harvested with 0.25% trypsin without EDTA when 80%~90% confluent. Before experiments, ECM was replaced with OPTI-MEM (Gibco) without FBS. All studies were performed using HUVECs of 2 to 8 passages [3638].

2.2. Immunocytochemistry

After incubated with inhibitors (MYR, DES, D609, and NOE), respectively, for 12 h, HUVECs grown on gelatin-coated coverslips were fixed in 4% formaldehyde for 10 min and then washed in PBS for three times. Cells were stained with an anti-ceramide IgM antibody (Alexis, 1 : 100) for 1 h at 37°C and followed by CY3-conjugated goat anti-mouse secondary antibody (Bioss, 1 : 100) for another 2 h at room temperature [3941]. Images were acquired using a custom-configured fluorescence microscope (Olympus FV500) [42]. The integrated fluorescence intensities were measured using the Image-Pro Plus software and normalized to the number of cells.

2.3. Intracellular Ceramide Extraction and Quantitation

Ceramide was extracted and quantified by HPLC-MS/MS (Thermo, LCQ DECA ) according to the principles described previously [4346]. For extraction of cellular lipids, cells were lysed with distilled water and homogenized by sonication after incubation with inhibitors for 12 h. Protein concentrations were measured and the equal amounts of protein (500 μg) were adjusted to the volume of 800 μL in 1 M NaCl. C12-ceramide (10 ng) was added to lysates as an internal standard and the resulting samples were extracted with chloroform/methanol (1 : 2) 3 mL for 3 h. Samples were then centrifuged at 3000 g, 5 min. Supernatants were transferred to the other tubes within CCL4 and 1 M NaCl 1 mL, respectively. After centrifugation, the lower organic phase was obtained and evaporated to near dryness under a gentle stream of dry N2. Meantime, samples were reconstituted by 100 μL methanol to measure ceramides C14, C16, C24:1, and C24 by HPLC-MS/MS. The levels of each ceramide species were determined by their relative abundance normalized to C12-ceramide and the gross of ceramides was quantified based on the standard curve which was constructed on ceramide standards (Avanti). The gross of these ceramides was used for statistics.

2.4. Cellular Uptake of oxLDL

oxLDL was labeled with fluorescein isothiocyanate (FITC; Biosharp) by a minor modification of a previously described method [47, 48]. In brief, oxLDL and FITC were mixed and incubated at 37°C for 2 h and then unbound FITC was removed by dialysis against PBS for 72 h at 4°C. Finally, FITC-oxLDL was stored at 4°C in the dark for further use. All procedures were performed in the dark. Cells were seeded on gelatin-coated glass coverslips in 24-well culture dishes and incubated at 37°C and 5% CO2. After being treated with the above inhibitors, respectively, for 9 h, cells were then incubated with 50 μg/mL FITC-oxLDL for 3 h. Images were obtained with a fluorescence microscope using a 40x objective. The integrated fluorescence intensities were measured using the Image-Pro Plus software and normalized to the number of cells.

2.5. oxLDL Retention in Isolated Umbilical Venous Wall

In a mixture of oxygen (95% O2 and 5% CO2) condition, the human umbilical venous rings were incubated with 50 μg/mL FITC-oxLDL and various inhibitors at 37°C for 3 h [47]. Then the tissues were frozen and sliced into thin sections of 8 μm with a freezing microtome (Leica CM1900) and further stained with DAPI. For each optical section, the space above the basilar membrane was defined as the region of interest (ROI). The fluorescence intensity was quantitated using Image-Pro Plus software. A weighted analysis was performed by first determining the area of fluorescence within the ROI of each optical section for three fluorescence intensity value ranges as follows: 160 to 190, 190 to 210, and 210 to 230. These three area measurements were then multiplied by 1, 3, or 5, respectively, to give greater weight to areas of highest intensity [49]. These weighted values were then summed for each optical section and divided by the area of ROI.

2.6. oxLDL Transcytosis

As described previously, the amount of oxLDL transcytosis was measured by a nonradioactive method in vitro [47, 48]. HUVECs were seeded on polyester membrane of costar transwell (6.5 mm diameter and 0.4 μm pore size) to form integrated cell monolayer. The integrity of cell monolayer was tested by a method described previously [50]. Two inserts of cell monolayers with equal integrity were divided into the same group: the noncompetitive insert and the competitive insert, respectively. Inhibitors were added to each group for 9 h. And then, the noncompetitive insert was incubated with 50 μg/mL FITC-oxLDL to determine the total amount of transendothelial oxLDL; paracellular transport was determined by incubation with 50 μg/mL FITC-oxLDL and 6-fold excess of unlabeled oxLDL (300 μg/mL) in competitive insert. After 3 h, samples were then collected from the outer chambers and further dialyzed against PBS to remove the free FITC. The relative fluorescence was measured via a fluorescence spectrophotometer (Tecan, Infinite F200PRO) with excitation and emission wavelengths of 490 nm and 520 nm, respectively. Meanwhile, background fluorescence determined by serum-free Opti-MEM was subtracted from the value of each sample. The amount of oxLDL transcytosis is the difference between the fluorescent intensity of the noncompetitive insert and the competitive insert.

2.7. Subendothelial oxLDL Retention In Vivo

Animals were treated in accordance with the guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and approved by the local animal care committee. Healthy C57BL/6J mice (18–20 g) were purchased from the Center of Experimental Animals (Tongji Medical College, Huazhong University of Science and Technology, China) and maintained in a controlled environment with a light/dark cycle of 12 h, a temperature of 20 ± 2°C, and a humidity of 50 ± 2%. Male C57BL/6J mice were randomly assigned to 6 treatment groups: groups 1-2 received 0.9% saline, groups 3–6 were intraperitoneally (i.p.) injected with myriocin 0.3 mg/kg three times over 5 days (days 1, 3, and 5) [51], desipramine 20 mg/kg/day for 5 days, D609 10 mg/kg for 12 h before sacrifice, and NOE 10 mg/kg/day for 5 days, respectively. C57 mice of groups 2–6 were injected via tail vein with FITC-oxLDL (50 μg/mouse) for 3 h before sacrifice, while mice of group 1 were injected with unlabeled oxLDL (50 μg/mouse). Mice were euthanized, and the hearts, spleens, and livers were quickly frozen in liquid nitrogen. Frozen sections of hearts, spleens, and livers were prepared as described previously [49, 52]. The sections were stained with DAPI. Due to the existence of spontaneous fluorescence in aortas, we use the difference in fluorescent intensity between the subendothelial layer and the whole vessel to stand for FITC-oxLDL fluorescent intensity. For each group, 20 sections were analyzed, which represent 5 interval sections per aorta from 4 mice.

2.8. Isolation of Cavolin-1-Enriched Membrane Raft Fractions

Caveolae-enriched membrane fractions were prepared by a detergent-free purification, as described previously [41, 53]. To isolate membrane raft fractions from the cell membrane, HUVECs were lysed in 2 mL 500 mmol/L Na2CO3 containing protease inhibitor cocktail. Cell extracts were homogenized with 15 strokes through a 25-gauge needle followed by sonication for 15 s three times on ice. Detecting the concentration of protein in the homogenate made sure that each group has equal amounts of protein. The final volume was adjusted to 2 mL with MBS containing 25 mmol/L 2-(N-morpholino)ethanesulfonic acid and 0.15 mol/L NaCl, pH 6.5. Homogenates were adjusted with 2 mL 90% sucrose density gradient medium prepared in MBS to 45% and overlaid with discontinuous 4 mL 30% and 4 mL 5% sucrose in the MBS buffer containing 250 mmol/L Na2CO3. Samples were then centrifuged at 39,000 rpm for 18 h at 4°C in a SW 41 rotor (Beckman Instruments). A total of 12 fractions per 1 mL were collected carefully from top to bottom. For immunoblot analysis of membrane raft-associated proteins, these fractions were precipitated by 10% cold trichloroacetic acid and washed with cold acetone, air-dried. The protein pellets were then dissolved in an SDS-PAGE lysis buffer for western blot analysis.

2.9. Western Blotting

After cells were incubated with the inhibitors, respectively, for 12 h, caveolin-1 enriched membrane fractions were isolated as described above and the final samples were detected by western blotting. The protein samples were separated by SDS-PAGE gel and then electrotransferred to PVDF membranes. Subsequently, blots were subjected to immunostaining with antibodies against Caveolin-1 (Cell Signaling Technology, 1 : 800), Cavin-1 (ANBO, 1 : 500), and lectin-like oxLDL receptor (Lox-1, WuXi AppTec, 1 : 1000). After incubation for 1 h with a peroxidase-conjugated secondary antibody (Abbkine, 1 : 10000), bands were visualized by an ECL western blotting detection system (NDR, Israel). The band intensities were quantified using ImageJ software.

2.10. Statistical Analysis

All data are expressed as the mean ± SEM from at least three separate experiments. Significant differences between multiple groups were examined using ANOVA with Duncan’s multiple-range testing. A value of was considered significant.

3. Results

3.1. Endogenous Cellular Ceramide Production Is Regulated by Ceramide Metabolizing Enzyme Inhibitors

To determine the effects of various inhibitors on ceramide metabolism, ceramide concentration was detected by two methods. The representative fluorescence microscopic images and semiquantitative results were shown in Figures 1(a) and 1(b). To further confirm the effects, we detected ceramides by HPLC/MS (Figure 1(c)). Results demonstrated that MYR and DES reduced ceramide concentration, while D609 and NOE increased ceramide concentration remarkably.

3.2. FITC-oxLDL Transcytosis across Endothelial Cell Monolayers

To determine whether the inhibitors alter the amount of oxLDL transport across HUVECs, we assayed the amount of oxLDL transcytosis across HUVECs. As shown in Figure 2, pretreatment with MYR or DES significantly decreased oxLDL transcytosis, while exposure to D609 or NOE significantly increased oxLDL transcytosis. These results were further confirmed by the observations of oxLDL uptake in cultured HUVECs. Since the oxLDL uptake by HUVECs is an intermediate phase of oxLDL transcytosis across HUVECs, it may also represent the amount of oxLDL transcytosis in a degree. As shown in Figures 3(a) and 3(b), fluorescence intensities in each individual cell were measured to reflect the amount of oxLDL uptake. It was found that the levels of oxLDL uptake were suppressed by MYR or DES, while elevated by D609 or NOE.

3.3. The Subendothelial Retention of oxLDL In Vitro

An experiment was conducted to test whether subendothelial retention of oxLDL would alter in the presence of various inhibitors. As summarized in Figures 4(a) and 4(b), more FITC-oxLDL accumulated in the region above the basilar membrane after D609 or NOE stimulation. However, the accumulation of FITC-oxLDL was significantly decreased in the presence of MYR or DES.

3.4. The Subendothelial Retention of oxLDL In Vivo

To validate the oxLDL transcytosis and subendothelial retention, the endothelial fluorescence intensities in aortic roots from C57 mouse were detected. Compared to mice injected with unlabeled oxLDL, aortas from mice injected with FITC-oxLDL showed stronger fluorescence intensities located under endothelium (Figure 5(a)). Similar to that shown in Figure 4, the space under endothelium in aortic root of mice treated with inhibitors accumulated more or less fluorescence. It was noted that, aortas from MYR-/DES-treated mice accumulated very little fluorescence under endothelium, while aortas from D609-/NOE-treated mice showed much stronger fluorescence signal. Supplemental Figure 1 (see Supplementary Material online at: http://dx.doi.org/10.1155/2014/823071) showed no difference in fluorescence accumulation in spleens or livers of mice in separate groups.

3.5. The Expression of LRs Components Related to oxLDL Transcytosis

Lipid rafts fractions were isolated as described before. Caveolin-1 enriched fractions (1 mL for each) were detected to determine LRs location (fractions 6 and 7) as shown in Figure 6(a). As shown in Figures 6(b) and 6(c), the expression of proteins involved in caveolae formation (caveolin-1 and cavin-1) as well as oxLDL receptor (Lox-1) could be regulated by inhibitors of ceramide related enzymes. Compared with control, MYR and DES significantly decreased the expressions of all proteins involved in oxLDL transport, while D609 and NOE increased the expressions.

4. Discussion

Ceramides are increasingly recognized to play essential roles in the pathogenesis of atherosclerosis [21, 5458]. In the present study, for the first time, we demonstrated that endogenously produced ceramides in endothelial cells significantly contributed to the transcytosis of oxLDL across the endothelial cell barrier and facilitated the subendothelial retention of these oxidized lipids, further promoting the progression of atherosclerosis.

LDL per se is a spherical nanoparticle composed of lipid molecules surrounded by apoB100, which mediates the molecular recognition of LDL with its receptors. As compared to other types of lipoproteins, LDL contains more sphingolipids and cholesterol and has a property of resistance to detergent at low temperatures [7]. Previous reports have indicated elevated plasma sphingolipid levels in AS [59], pointing to the importance of ceramide in AS. But how ceramides affect atherogenesis remains to be further elucidated.

By immunostaining and HPLC-MS analysis, we first confirmed the inhibiting effects of the inhibitors of multiple enzymes involved in ceramide metabolism. We found that both de novo ceramide synthesis inhibitor, myriocin, and acid sphingomyelinase inhibitor, desipramine, could reduce the production of ceramide. However, ceramidase inhibitor, NOE, and sphingomyelin synthase inhibitor, D609, significantly upregulated the production of ceramide.

In an established in vitro model of oxLDL transcytosis across endothelial cell monolayer, we documented that myriocin and desipramine reduced the transcytosis of oxLDL; however, NOE and D609 significantly accelerated the transcytosis of oxLDL across endothelial cells. In this model, we used the difference of fluorescence between control and competitive inserts, which represent the total and paracellular transport of oxLDL, respectively, to reflect the transcytosis of oxLDL across endothelial cells. This method of detecting transcytosis had been validated by previous studies [47, 48]. The alterations of the transcytosis induced by various inhibitors in the present study are in consistence with the alterations of intracellular ceramide production, strongly indicating that the endogenously produced ceramides facilitate the transcytosis of oxLDL across endothelial cells. For oxLDL to be transcytosed across endothelial cells, the oxLDL particles must be endocytosed in the lumen side of the endothelial cells and then be transferred to the basolateral side and further be exocytosed to the subendothelial space. During this process, an intermediate state of transcytosis is that these particles had already been endocytosed into the cytosol but had not been released yet. Therefore, the intracellular concentration of oxLDL particles also reflects the activity of transcytosis. The decrease of oxLDL particles in myriocin and desipramine treated cells, whereas the increase of oxLDL particles in NOE and D609 treated endothelial cells, further supports the promoting roles of ceramide in regulating oxLDL transcytosis. In isolated vascular preparations, when the umbilical vascular segments were incubated with fluorescence-labeled oxLDL particles, these particles can be transported to the subendothelial space in the vessel walls. Myriocin and desipramine, which inhibited the production of intracellular ceramide, also reduced the subendothelial retention of oxLDL. Vice versa, NOE and D609, which upregulated the ceramide level, increased the subendothelial retention of oxLDL in vessel walls.

To further confirm these effects in in vivo level, we also conducted animal experiments. Similar to those observations in cultured endothelial cells and isolated vascular segments, the two inhibitors, myriocin and desipramine, which suppressed the production of ceramide, attenuated the accumulation of oxLDL in the mouse aorta walls. However, NOE and D609, which stimulated the ceramide production, enhanced the subendothelial retention of oxLDL in vessel walls.

After the oxidative modification of LDL, oxLDL is generated, in which the sphingomyelin hydrolysis rate is 5-6 times of the naive LDL [60]; ceramide levels in oxLDL particles in AS lesions are 10–50 times the ceramide levels in plasma natural LDL [61]. Our results are in consistence with several observations in previous reports. Devlin CM reported that ASM plays a very important role in the pathogenesis of AS. AS lesions in double gene-deficient mice from hybridization of ASM knockout Asm−/− mice and apolipoprotein E knockout Apoe−/− mice were significantly smaller than those in Apoe−/− mice [49]. Loidl et al. reported that oxidation of phospholipids of modified LDL activates intracellular ASM [62]. These observations also strongly support the essential role of ceramide in the formation of atherosclerosis. However, McGovern et al. reported that patients of Niemann-Pick disease types A and B with a deficiency in ASM activity had low HDL and elevated LDL in plasma and had high incidences of coronary atherosclerosis [63]. This controversy may be due to the different roles of ASM in the metabolism of lipid profiles in liver and in the lipoprotein retention in vascular wall. On one side, ASM appears to be essential to maintain the normal LDL and VLDL metabolism pathway. ASM deficiency in Niemann-Pick disease results in the elevation of plasma LDL and reduction of HDL, which are established risk factors of atherosclerosis. On the other side, ASM may directly promote the retention of lipoprotein particles into the subendothelial space of vascular wall and facilitate the progression of atherosclerosis. Our study focuses on the second aspect of ASM in vascular wall. This is very similar to the roles the LDL receptor (LDLR) plays in atherosclerosis. On one side, LDLR mediates the retention of LDL into the vascular wall and promotes the incidence of AS [64, 65]. On the other side, Ldlr−/− mice exhibit typical hypercholesterol and are more vulnerable to atherosclerosis [66, 67]. A recent paper by Li et al. suggested that the control of lysosome trafficking and fusion by ASM is essential to a normal autophagic flux in coronary arterial smooth muscle cells [68]. Basically, there is no doubt that ASM is beneficial under physiological conditions, but, in chronic pathological conditions such as atherosclerosis, the ASM activities are persistently upregulated and would in turn drive the progression of diseases [49, 69]. In this situation, inhibition of ASM activity may be the right strategy for therapy.

We also preliminarily studied the mechanism why ceramide contributed to the transcytosis of oxLDL. Basically, oxLDL transcytosis in endothelial cells is mediated by its receptor, Lox-1 [70, 71], as well as many other essential proteins involved in endocytosis or exocytosis, including the caveolae structure protein, caveolin-1 [71, 72], and caveolae associated protein, cavin-1 [72, 73]. Lox-1 and caveolin-1 are both residing in membrane raft domains of endothelial cells. Cavin-1 also binds to caveolin-1 to help maintain the integrity of caveolae. Since ceramides are much less polar than sphingomyelin, these hydrophobic lipids are more ready to fuse simultaneously and contribute to the integrity of membrane raft structures [30], which will facilitate the lipid raft-dependent transcytosis. We studied whether ceramide could alter the expressions of these oxLDL transcytosis-related proteins in membrane rafts. We found that the expressions of Lox-1, caveolin-1, and cavin-1 in membrane raft domains were also significantly regulated by ceramide metabolizing enzyme inhibitors. DES and MYR decreased the expression of Lox-1, caveolin-1, and cavin-1 in membrane rafts. Whereas NOE and D609 upregulated the expressions of these proteins in membrane rafts. Our observations partially explain the critical role of ceramide in the transcytosis of oxLDL across endothelial cells. Some previous studies have also shown that oxLDL induced lipid rafts clustering in human coronary arterial endothelial cells [74] and Lox-1 increased in lipid rafts after oxLDL treatment [53]. oxLDL may also affect ceramide production in lipid rafts [74, 75]. These observations imply that oxLDL per se may also elicit a signaling to facilitate its own transcytosis, which would form a feedback forward mechanism and amplify the transcytosis process.

Collectively, both the in vitro and in vivo evidences provided in the present study strongly point to a conclusion that oxidized LDL, oxLDL, is able to traffic across the endothelial barrier through transcytosis and these processes are highly regulated by intracellular ceramide. Endogenous ceramide significantly promotes the transcytosis of oxLDL across endothelial cells. Therefore, novel compounds designed to manipulate the metabolism of ceramide production through targeting related enzymes may provide novel strategies for the prevention or treatment of atherosclerosis-related disorders.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Wenjing Li and Xiaoyan Yang contributed equally to this work.


This study was supported by Grants from the National Natural Science Foundation of China (81072634, 81373413, 81000080, and 30870997) and Grants from the Ministry of Education of China (NCET-10-0409, 2013YGYL008, and 2011TS069).

Supplementary Materials

As described in methods 2.7, frozen sections of spleens and livers from each group were prepared. There is no significant difference of fluorescence between groups.

  1. Supplementary Material


  1. A. C. Lindsay and R. P. Choudhury, “Form to function: current and future roles for atherosclerosis imaging in drug development,” Nature Reviews Drug Discovery, vol. 7, no. 6, pp. 517–529, 2008. View at: Publisher Site | Google Scholar
  2. K. Skålén, M. Gustafsson, E. K. Rydberg et al., “Subendothelial retention of atherogenic lipoproteins in early atherosclerosis,” Nature, vol. 417, no. 6890, pp. 750–754, 2002. View at: Publisher Site | Google Scholar
  3. B. Staels, “Cardiovascular biology: a cholesterol tether,” Nature, vol. 417, no. 6890, pp. 699–701, 2002. View at: Google Scholar
  4. I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, 2007. View at: Publisher Site | Google Scholar
  5. I. Tabas, “Macrophage death and defective inflammation resolution in atherosclerosis,” Nature Reviews Immunology, vol. 10, no. 1, pp. 36–46, 2010. View at: Publisher Site | Google Scholar
  6. P. G. Frank, S. Pavlides, and M. P. Lisanti, “Caveolae and transcytosis in endothelial cells: role in atherosclerosis,” Cell and Tissue Research, vol. 335, no. 1, pp. 41–47, 2009. View at: Publisher Site | Google Scholar
  7. R. M. Krauss and D. J. Burke, “Identification of multiple subclasses of plasma low density lipoproteins in normal humans,” Journal of Lipid Research, vol. 23, no. 1, pp. 97–104, 1982. View at: Google Scholar
  8. N. Simionescu, M. Simionescu, and G. E. Palade, “Open junctions in the endothelium of the postcapillary venules of the diaphragm,” Journal of Cell Biology, vol. 79, no. 1, pp. 27–44, 1978. View at: Google Scholar
  9. P. L. Tuma and A. L. Hubbard, “Transcytosis: crossing cellular barriers,” Physiological Reviews, vol. 83, no. 3, pp. 871–932, 2003. View at: Google Scholar
  10. S. Ehara, M. Ueda, T. Naruko et al., “Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes,” Circulation, vol. 103, no. 15, pp. 1955–1960, 2001. View at: Google Scholar
  11. S. Xu, S. Ogura, J. Chen, P. J. Little, J. Moss, and P. Liu, “LOX-1 in atherosclerosis: biological functions and pharmacological modifiers,” Cellular and Molecular Life Sciences, vol. 70, no. 16, pp. 2859–2872, 2013. View at: Publisher Site | Google Scholar
  12. S. Tsimikas and J. L. Witztum, “Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk,” Circulation, vol. 103, no. 15, pp. 1930–1932, 2001. View at: Google Scholar
  13. E. Verhoye and M. R. Langlois, “Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 2, pp. 128–137, 2009. View at: Publisher Site | Google Scholar
  14. S. Staubach and F.-G. Hanisch, “Lipid rafts: signaling and sorting platforms of cells and their roles in cancer,” Expert Review of Proteomics, vol. 8, no. 2, pp. 263–277, 2011. View at: Publisher Site | Google Scholar
  15. S. Jin, F. Zhou, F. Katirai, and P.-L. Li, “Lipid raft redox signaling: molecular mechanisms in health and disease,” Antioxidants & Redox Signaling, vol. 15, no. 4, pp. 1043–1083, 2011. View at: Publisher Site | Google Scholar
  16. S. Jin and F. Zhou, “Lipid raft redox signaling platforms in vascular dysfunction: features and mechanisms,” Current Atherosclerosis Reports, vol. 11, no. 3, pp. 220–226, 2009. View at: Publisher Site | Google Scholar
  17. P. Lajoie and I. R. Nabi, “Lipid rafts, caveolae, and their endocytosis,” International Review of Cell and Molecular Biology, vol. 282, pp. 135–163, 2010. View at: Publisher Site | Google Scholar
  18. D. Lingwood, H.-J. Kaiser, I. Levental, and K. Simons, “Lipid rafts as functional heterogeneity in cell membranes,” Biochemical Society Transactions, vol. 37, no. 5, pp. 955–960, 2009. View at: Publisher Site | Google Scholar
  19. K. Simons and E. Ikonen, “Functional rafts in cell membranes,” Nature, vol. 387, no. 6633, pp. 569–572, 1997. View at: Publisher Site | Google Scholar
  20. J. D. Symons and E. D. Abel, “Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide,” Reviews in Endocrine and Metabolic Disorders, vol. 14, no. 1, pp. 59–68, 2013. View at: Publisher Site | Google Scholar
  21. J. Bismuth, P. Lin, Q. Yao, and C. Chen, “Ceramide: a common pathway for atherosclerosis?” Atherosclerosis, vol. 196, no. 2, pp. 497–504, 2008. View at: Publisher Site | Google Scholar
  22. S. Elojeimy, D. H. Holman, X. Liu et al., “New insights on the use of desipramine as an inhibitor for acid ceramidase,” FEBS Letters, vol. 580, no. 19, pp. 4751–4756, 2006. View at: Publisher Site | Google Scholar
  23. R. Bhatia, K. Matsushita, M. Yamakuchi, C. N. Morrell, W. Cao, and C. J. Lowenstein, “Ceramide triggers Weibel-Palade body exocytosis,” Circulation Research, vol. 95, no. 3, pp. 319–324, 2004. View at: Publisher Site | Google Scholar
  24. M. Kölzer, N. Werth, and K. Sandhoff, “Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine,” FEBS Letters, vol. 559, no. 1–3, pp. 96–98, 2004. View at: Publisher Site | Google Scholar
  25. T.-S. Park, R. L. Panek, M. D. Rekhter et al., “Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice,” Atherosclerosis, vol. 189, no. 2, pp. 264–272, 2006. View at: Publisher Site | Google Scholar
  26. P. Keul, K. Sattler, and B. Levkau, “HDL and its sphingosine-1-phosphate content in cardioprotection,” Heart Failure Reviews, vol. 12, no. 3-4, pp. 301–306, 2007. View at: Publisher Site | Google Scholar
  27. E. Houben, J. P. Hachem, K. de Paepe, and V. Rogiers, “Epidermal ceramidase activity regulates epidermal desquamation via stratum corneum acidification,” Skin Pharmacology and Physiology, vol. 21, no. 2, pp. 111–118, 2008. View at: Publisher Site | Google Scholar
  28. A. Meng, C. Luberto, P. Meier et al., “Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells,” Experimental Cell Research, vol. 292, no. 2, pp. 385–392, 2004. View at: Publisher Site | Google Scholar
  29. Z. Li, T. K. Hailemariam, H. Zhou et al., “Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization,” Biochimica et Biophysica Acta, vol. 1771, no. 9, pp. 1186–1194, 2007. View at: Publisher Site | Google Scholar
  30. S. Jin, F. Yi, and P.-L. Li, “Contribution of lysosomal vesicles to the formation of lipid raft redox signaling platforms in endothelial cells,” Antioxidants & Redox Signaling, vol. 9, no. 9, pp. 1417–1426, 2007. View at: Publisher Site | Google Scholar
  31. S. Jin, F. Yi, F. Zhang, J. L. Poklis, and P.-L. Li, “Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 2056–2062, 2008. View at: Publisher Site | Google Scholar
  32. A. Y. Zhang, F. Yi, S. Jin et al., “Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells,” Antioxidants & Redox Signaling, vol. 9, no. 7, pp. 817–828, 2007. View at: Publisher Site | Google Scholar
  33. J. M. Harouse, R. G. Collman, and F. Gonzalez-Scarano, “Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line,” Journal of Virology, vol. 69, no. 12, pp. 7383–7390, 1995. View at: Google Scholar
  34. J.-T. Jan, S. Chatterjee, and D. E. Griffin, “Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide,” Journal of Virology, vol. 74, no. 14, pp. 6425–6432, 2000. View at: Publisher Site | Google Scholar
  35. V. Teichgräber, M. Ulrich, N. Endlich et al., “Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis,” Nature Medicine, vol. 14, no. 4, pp. 382–391, 2008. View at: Publisher Site | Google Scholar
  36. A. L. Cheung, “Isolation and culture of human umbilical vein endothelial cells (HUVEC),” Current Protocols in Microbiology, 2007. View at: Publisher Site | Google Scholar
  37. B. Baudin, A. Bruneel, N. Bosselut, and M. Vaubourdolle, “A protocol for isolation and culture of human umbilical vein endothelial cells,” Nature Protocols, vol. 2, no. 3, pp. 481–485, 2007. View at: Publisher Site | Google Scholar
  38. E. A. Jaffe, R. L. Nachman, C. G. Becker, and C. R. Minick, “Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria,” The Journal of Clinical Investigation, vol. 52, no. 11, pp. 2745–2756, 1973. View at: Google Scholar
  39. S.-J. Jia, S. Jin, F. Zhang, F. Yi, W. L. Dewey, and P.-L. Li, “Formation and function of ceramide-enriched membrane platforms with CD38 during M1-receptor stimulation in bovine coronary arterial myocytes,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 295, no. 4, pp. H1743–H1752, 2008. View at: Publisher Site | Google Scholar
  40. G. Vielhaber, L. Brade, B. Lindner et al., “Mouse anti-ceramide antiserum: a specific tool for the detection of endogenous ceramide,” Glycobiology, vol. 11, no. 6, pp. 451–457, 2001. View at: Google Scholar
  41. L. Wang, H. Zhen, W. Yao et al., “Lipid raft-dependent activation of dual oxidase 1/H2o2/NF-κB pathway in bronchial epithelial cells,” American Journal of Physiology: Cell Physiology, vol. 301, no. 1, pp. C171–C180, 2011. View at: Publisher Site | Google Scholar
  42. V. Zinchuk and O. Grossenbacher-Zinchuk, “Recent advances in quantitative colocalization analysis: focus on neuroscience,” Progress in Histochemistry and Cytochemistry, vol. 44, no. 3, pp. 125–172, 2009. View at: Publisher Site | Google Scholar
  43. S. L. Schissel, X.-C. Jiang, J. Tweedie-Hardman et al., “Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for athereosclerotic lesion development,” The Journal of Biological Chemistry, vol. 273, no. 5, pp. 2738–2746, 1998. View at: Publisher Site | Google Scholar
  44. A. Strelow, K. Bernardo, S. Adam-Klages et al., “Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death,” The Journal of Experimental Medicine, vol. 192, no. 5, pp. 601–612, 2000. View at: Publisher Site | Google Scholar
  45. P. J. Honeycutt and J. E. Niedel, “Cytochalasin B enhancement of the diacylglycerol response in formyl peptide-stimulated neutrophils,” The Journal of Biological Chemistry, vol. 261, no. 34, pp. 15900–15905, 1986. View at: Google Scholar
  46. G. Seumois, M. Fillet, L. Gillet et al., “De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis,” Journal of Leukocyte Biology, vol. 81, no. 6, pp. 1477–1486, 2007. View at: Publisher Site | Google Scholar
  47. F. Bian, X. Yang, F. Zhou et al., “CRP promotes atherosclerosis by increasing LDL transcytosis across endothelial cells,” British Journal of Pharmacology, 2014. View at: Publisher Site | Google Scholar
  48. Y. Zhang, X. Yang, F. Bian et al., “TNF- α promotes early atheros clerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ,” Journal of Molecular and Cellular Cardiology, vol. 72, pp. 85–94, 2014. View at: Publisher Site | Google Scholar
  49. C. M. Devlin, A. R. Leventhal, G. Kuriakose, E. H. Schuchman, K. J. Williams, and I. Tabas, “Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 10, pp. 1723–1730, 2008. View at: Publisher Site | Google Scholar
  50. Z. Cankova, J.-D. Huang, H. S. Kruth, and M. Johnson, “Passage of low-density lipoproteins through Bruch's membrane and choroid,” Experimental Eye Research, vol. 93, no. 6, pp. 947–955, 2011. View at: Publisher Site | Google Scholar
  51. E. N. Glaros, W. S. Kim, and B. Garner, “Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition,” Clinical Science, vol. 118, no. 12, pp. 727–736, 2010. View at: Publisher Site | Google Scholar
  52. J. C. Frias, K. J. Williams, E. A. Fisher, and Z. A. Fayad, “Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques,” Journal of the American Chemical Society, vol. 126, no. 50, pp. 16316–16317, 2004. View at: Publisher Site | Google Scholar
  53. S. Matarazzo, M. C. Quitadamo, R. Mango, S. Ciccone, G. Novelli, and S. Biocca, “Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption,” Molecular Pharmacology, vol. 82, no. 2, pp. 246–254, 2012. View at: Publisher Site | Google Scholar
  54. L. Chun, Z. Junlin, W. Aimin, L. Niansheng, C. Benmei, and L. Minxiang, “Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats,” Diabetes Research and Clinical Practice, vol. 93, no. 1, pp. 77–85, 2011. View at: Publisher Site | Google Scholar
  55. K. Kobayashi, E. Nagata, K. Sasaki, M. Harada-Shiba, S. Kojo, and H. Kikuzaki, “Increase in secretory sphingomyelinase activity and specific ceramides in the aorta of apolipoprotein E knockout mice during aging,” Biological and Pharmaceutical Bulletin, vol. 36, no. 7, pp. 1192–1196, 2013. View at: Publisher Site | Google Scholar
  56. D. Gao, C. Pararasa, C. R. Dunston, C. J. Bailey, and H. R. Griffiths, “Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis,” Free Radical Biology and Medicine, vol. 53, no. 4, pp. 796–806, 2012. View at: Publisher Site | Google Scholar
  57. X.-C. Jiang, I. J. Goldberg, and T.-S. Park, “Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy,” Advances in Experimental Medicine and Biology, vol. 721, pp. 19–39, 2011. View at: Publisher Site | Google Scholar
  58. Y. Fan, F. Shi, J. Liu et al., “Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 11, pp. 2114–2120, 2010. View at: Publisher Site | Google Scholar
  59. X.-C. Jiang, F. Paultre, T. A. Pearson et al., “Plasma sphingomyelin level as a risk factor for coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 12, pp. 2614–2618, 2000. View at: Google Scholar
  60. M. Grandl, S. M. Bared, G. Liebisch, T. Werner, S. Barlage, and G. Schmitz, “E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human macrophages,” Cytometry A, vol. 69, no. 3, pp. 189–191, 2006. View at: Publisher Site | Google Scholar
  61. S. L. Schissel, J. Tweedie-Hardman, J. H. Rapp, G. Graham, K. J. Williams, and I. Tabas, “Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins,” The Journal of Clinical Investigation, vol. 98, no. 6, pp. 1455–1464, 1996. View at: Google Scholar
  62. A. Loidl, E. Sevcsik, G. Riesenhuber, H.-P. Deigner, and A. Hermetter, “Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells,” The Journal of Biological Chemistry, vol. 278, no. 35, pp. 32921–32928, 2003. View at: Publisher Site | Google Scholar
  63. M. M. McGovern, T. Pohl-Worgall, R. J. Deckelbaum et al., “Lipid abnormalities in children with types A and B Niemann Pick disease,” The Journal of Pediatrics, vol. 145, no. 1, pp. 77–81, 2004. View at: Publisher Site | Google Scholar
  64. G. Cichon, T. Willnow, S. Herwig et al., “Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage,” The Journal of Gene Medicine, vol. 6, no. 2, pp. 166–175, 2004. View at: Publisher Site | Google Scholar
  65. O. C. Hibbitt, E. McNeil, M. M. P. Lufino, L. Seymour, K. Channon, and R. Wade-Martins, “Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs,” Molecular Therapy, vol. 18, no. 2, pp. 317–326, 2010. View at: Publisher Site | Google Scholar
  66. S. Zadelaar, R. Kleemann, L. Verschuren et al., “Mouse models for atherosclerosis and pharmaceutical modifiers,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 8, pp. 1706–1721, 2007. View at: Publisher Site | Google Scholar
  67. L. Powell-Braxton, M. Véniant, R. D. Latvala et al., “A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet,” Nature Medicine, vol. 4, no. 8, pp. 934–938, 1998. View at: Publisher Site | Google Scholar
  68. X. Li, M. Xu, A. L. Pitzer et al., “Control of autophagy maturation by acid sphingomyelinase in mouse coronary arterial smooth muscle cells: protective role in atherosclerosis,” Journal of Molecular Medicine, 2014. View at: Publisher Site | Google Scholar
  69. S. Marathe, G. Kuriakose, K. J. Williams, and I. Tabas, “Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 11, pp. 2648–2658, 1999. View at: Google Scholar
  70. M. Kumano-Kuramochi, Q. Xie, S. Kajiwara, S. Komba, T. Minowa, and S. Machida, “Lectin-like oxidized LDL receptor-1 is palmitoylated and internalizes ligands via caveolae/raft-dependent endocytosis,” Biochemical and Biophysical Research Communications, vol. 434, no. 3, pp. 594–599, 2013. View at: Publisher Site | Google Scholar
  71. S.-W. Sun, X.-Y. Zu, Q.-H. Tuo et al., “Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells,” Acta Pharmacologica Sinica, vol. 31, no. 10, pp. 1336–1342, 2010. View at: Publisher Site | Google Scholar
  72. A. Dávalos, C. Fernández-Hernando, G. Sowa et al., “Quantitative proteomics of caveolin-1-regulated proteins: characterization of polymerase I and transcript release factor/cavin-1 in endothelial cells,” Molecular & Cellular Proteomics, vol. 9, no. 10, pp. 2109–2124, 2010. View at: Publisher Site | Google Scholar
  73. M. M. Hill, M. Bastiani, R. Luetterforst et al., “PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function,” Cell, vol. 132, no. 1, pp. 113–124, 2008. View at: Publisher Site | Google Scholar
  74. Y. M. Wei, X. Li, J. Xiong et al., “Attenuation by statins of membrane raft-redox signaling in coronary arterial endothelium,” The Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 2, pp. 170–179, 2013. View at: Publisher Site | Google Scholar
  75. Y.-X. Liu, G.-Z. Han, T. Wu et al., “Protective effect of α-lipoic acid on oxidized low density lipoprotein-induced human umbilical vein endothelial cell injury,” Pharmacological Reports, vol. 63, no. 5, pp. 1180–1188, 2011. View at: Google Scholar

Copyright © 2014 Wenjing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.